PBLA vs. HSTO, LSDI, NBSE, GRI, INM, CMRA, GLMD, ATNF, PRFX, and QLGN
Should you be buying Panbela Therapeutics stock or one of its competitors? The main competitors of Panbela Therapeutics include Histogen (HSTO), Lucy Scientific Discovery (LSDI), NeuBase Therapeutics (NBSE), GRI Bio (GRI), InMed Pharmaceuticals (INM), Comera Life Sciences (CMRA), Galmed Pharmaceuticals (GLMD), 180 Life Sciences (ATNF), PainReform (PRFX), and Qualigen Therapeutics (QLGN). These companies are all part of the "pharmaceutical preparations" industry.
Histogen (NASDAQ:HSTO) and Panbela Therapeutics (NASDAQ:PBLA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, valuation, institutional ownership, media sentiment, risk, profitability, dividends, community ranking and analyst recommendations.
Histogen has higher revenue and earnings than Panbela Therapeutics. Histogen is trading at a lower price-to-earnings ratio than Panbela Therapeutics, indicating that it is currently the more affordable of the two stocks.
Histogen has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500. Comparatively, Panbela Therapeutics has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.
Panbela Therapeutics has a consensus target price of $500.00, indicating a potential upside of 131,099.16%. Given Histogen's higher possible upside, analysts plainly believe Panbela Therapeutics is more favorable than Histogen.
Panbela Therapeutics has a net margin of 0.00% compared to Panbela Therapeutics' net margin of -65,142.11%. Panbela Therapeutics' return on equity of -136.13% beat Histogen's return on equity.
4.4% of Panbela Therapeutics shares are owned by institutional investors. 3.3% of Histogen shares are owned by company insiders. Comparatively, 0.0% of Panbela Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
In the previous week, Panbela Therapeutics had 3 more articles in the media than Histogen. MarketBeat recorded 3 mentions for Panbela Therapeutics and 0 mentions for Histogen. Panbela Therapeutics' average media sentiment score of 0.00 equaled Histogen'saverage media sentiment score.
Panbela Therapeutics received 11 more outperform votes than Histogen when rated by MarketBeat users. Likewise, 69.23% of users gave Panbela Therapeutics an outperform vote while only 58.33% of users gave Histogen an outperform vote.
Summary
Panbela Therapeutics beats Histogen on 9 of the 15 factors compared between the two stocks.
Get Panbela Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PBLA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PBLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Panbela Therapeutics Competitors List
Related Companies and Tools
